Melbourne biopharmaceutical company Opthea has completed the patient recruitment phase for the latest trial of its novel therapy for diabetic macular edema (DME). Read more
Major Melbourne study a world-first for AMD
An Australian-led study has received $5 million to undertake the world’s most intensive investigation into why a particular group of age-related macular degeneration (AMD) patients are at greater risk of vision loss. Read more
Novartis targets Europe for next-generation AMD treatment
Novartis’ new therapy for neovascular age-related macular degeneration (nAMD) has advanced part-way through the European regulatory process after winning the approval of independent advisors. Read more
Warmth may improve effectiveness of anti-VEGF injections
Inconsistent or ineffective age-related macular degeneration (AMD) treatments might be solved by an easy solution, according to new research from the California Institute of Technology. Read more
Public funding for standalone MIGS procedures a step closer
Government advisors have recommended minimally invasive glaucoma surgery (MIGS) should be publicly funded as a standalone procedure, following extensive campaigning from Australia’s ophthalmic community. Read more
Australian biotech raises an additional $50 million for AMD drug
Melbourne-based biotech company Opthea has announced it has secured commitments from both Australian and international investors for an additional $50 million to put towards the development of its treatment for neovascular age-related macular degeneration (AMD). Read more
Progress made towards genetic test for myopia
Researchers from the UK have developed a genetic test capable of predicting an individual’s risk of developing childhood myopia. Read more
Locally developed glaucoma device leads to new Indonesian partnerships
The Lions Eye Institute (LEI) is strengthening its ties with Indonesian researchers following the successful launch of a new glaucoma drainage device produced for only one-tenth of the cost of competing products. Read more
Biogen unveils plan to commercialise Eylea and Lucentis generics
Multinational biotech company Biogen has proposed a deal worth up to US$310 million (AU$453 m) to supply biosimilar treatments of Lucentis and Eylea to major global markets, including Australia. Read more
Traces of anti-VEGF drugs found in breast milk
Anti-vascular endothelial growth factor (anti-VEGF) drugs have been identified in breast milk, prompting warnings from the researchers that the use of these medications during breastfeeding could affect developing infants. Read more